Compare UDR & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDR | PEN |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.8B |
| IPO Year | 1994 | 2015 |
| Metric | UDR | PEN |
|---|---|---|
| Price | $37.57 | $326.52 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 16 |
| Target Price | $40.35 | ★ $360.14 |
| AVG Volume (30 Days) | ★ 3.4M | 476.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | 334.62 | ★ 1155.56 |
| EPS | 0.57 | ★ 0.82 |
| Revenue | ★ $1,712,317,000.00 | $1,403,665,000.00 |
| Revenue This Year | N/A | $14.34 |
| Revenue Next Year | $2.80 | $13.71 |
| P/E Ratio | ★ $64.85 | $393.35 |
| Revenue Growth | 2.42 | ★ 17.50 |
| 52 Week Low | $32.94 | $221.26 |
| 52 Week High | $42.27 | $362.41 |
| Indicator | UDR | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 49.53 |
| Support Level | $37.40 | $321.38 |
| Resistance Level | $37.81 | $335.61 |
| Average True Range (ATR) | 0.66 | 2.26 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 87.25 | 82.67 |
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized; and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.